Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001663140 | SCV001872484 | uncertain significance | not provided | 2023-02-22 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002495982 | SCV002775803 | uncertain significance | Rubinstein-Taybi syndrome due to CREBBP mutations; Menke-Hennekam syndrome 1 | 2021-10-20 | criteria provided, single submitter | clinical testing | |
Molecular Genetics, |
RCV003994317 | SCV004812556 | uncertain significance | Rubinstein-Taybi syndrome due to CREBBP mutations | 2022-03-03 | criteria provided, single submitter | clinical testing | This sequence change in CREBBP is predicted to replace tyrosine with cysteine at codon 1214, p.(Tyr1214Cys). The tyrosine residue is highly conserved (100 vertebrates, UCSC), and is located in a Cys/His rich region. There is a large physicochemical difference between tyrosine and cysteine. The highest population minor allele frequency in gnomAD v3.1 (absent in gnomAD v2.1) is 0.005% (2/41,436 alleles) in the African/African American population. To our knowledge, this variant has not been reported in the literature in any individuals with CREBBP-related conditions. The variant has been reported as a variant of uncertain significance (ClinVar ID: 1253583). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (6/6 algorithms). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: PP3. |
Prevention |
RCV004743559 | SCV005344443 | uncertain significance | CREBBP-related disorder | 2024-03-20 | no assertion criteria provided | clinical testing | The CREBBP c.3641A>G variant is predicted to result in the amino acid substitution p.Tyr1214Cys. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |